CSWYY OTC
China Shineway Pharmaceutical Group Limited
1W: +13.1%
1M: +26.9%
3M: +11.6%
YTD: +11.6%
1Y: +11.6%
3Y: +26.6%
5Y: +20.1%
$21.49
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$3.0B
-19.3% ▼
5Y CAGR: +2.8%
Gross Profit
$2.2B
-22.2% ▼
5Y CAGR: +2.1%
Operating Income
$663M
-21.3% ▼
5Y CAGR: +9.5%
Net Income
$924M
+10.0% ▲
5Y CAGR: +25.7%
EPS (Diluted)
$489.40
+10.2% ▲
5Y CAGR: +25.7%
EBITDA
$732M
-40.0% ▼
5Y CAGR: +3.4%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $4.0B | $4.5B | $3.8B | $3.0B |
| YoY Growth | +21.4% | +22.6% | +14.3% | -16.4% | -19.3% |
| Cost of Revenue | $813M | $1.0B | $1.1B | $946M | $846M |
| Gross Profit | $2.4B | $2.9B | $3.4B | $2.8B | $2.2B |
| Gross Margin | 74.8% | 74.4% | 75.1% | 75.0% | 72.3% |
| R&D Expenses | $113M | $117M | $110M | $101M | $100M |
| SG&A Expenses | $1.8B | $2.1B | $2.3B | $1.9B | $1.4B |
| Operating Expenses | $1.8B | $2.1B | $2.4B | $2.0B | $1.5B |
| Operating Income | $534M | $714M | $976M | $843M | $663M |
| Operating Margin | 16.6% | 18.1% | 21.6% | 22.3% | 21.8% |
| Interest Expense | $1M | $630K | $3M | $6M | $6M |
| Income Before Tax | $720M | $917M | $1.2B | $1.1B | $1.2B |
| Tax Expense | $163M | $194M | $271M | $306M | $311M |
| Net Income | $557M | $723M | $970M | $840M | $924M |
| Net Margin | 17.3% | 18.3% | 21.5% | 22.2% | 30.3% |
| EPS (Diluted) | $296.00 | $384.00 | $513.40 | $444.00 | $489.40 |
| EBITDA | $904M | $1.1B | $1.4B | $1.2B | $732M |
| Shares Outstanding | 2M | 2M | 2M | 2M | 2M |